KR20200020542A - Sustained release preparation of cilostazol - Google Patents

Abstract

The present invention relates to a sustained-release formulation of cilostazol, comprising: cilostazol or pharmaceutically acceptable salt thereof; and, as a sustained-release matrix base, a neutral water-insoluble (meth)acrylic acid copolymer. The sustained-release formulation of the present invention has increased fluidity and has an effect of being suitable for mass production.

Description

Cilostazol sustained-release preparation {SUSTAINED RELEASE PREPARATION OF CILOSTAZOL}

The present invention relates to cilostazol sustained release formulations comprising cilostazol or a pharmaceutically acceptable salt thereof and a neutral water insoluble methacrylic acid copolymer as a sustained release matrix base.

Cilostazol is a 6- [4- (1-cyclohexyl-1H-tetrazol-5-yl) -butoxy] -3,4-dihydro- which is a quinolinone compound represented by the following formula (1): 2 (1H) -quinolinone, which is a selective inhibitor of representative intracellular cAMP PDE type III (cyclic AMP phosphodiesterase type III).

[Formula 1]

Cilostazol inhibits PDE activity upon body absorption, inhibits platelet aggregation and dilates blood vessels, thereby inhibiting blood coagulation, improving central blood circulation, anti-inflammatory, anti-ulcer, lowering blood pressure, preventing and treating asthma and cerebral infarction, brain circulation Since it shows an action of improvement, etc., it is widely used as an antithrombotic agent, a brain circulation improving agent, an anti-inflammatory agent, an anti-tumor agent, an antihypertensive agent, and an anti-asthma agent.

Conventional cilostazol formulations are administered orally twice a day, the patient's compliance with the medication is poor, causing oral administration, causing a rapid rise in blood drug concentrations, causing side effects such as headache, headache, tachycardia, etc. It is known. In addition, cilostazol is a poorly water-soluble drug having a water solubility of 1 μg / ml or less, and is mainly absorbed from the upper gastrointestinal tract and decreases absorption toward the lower intestinal tract. It may decrease.

Accordingly, in order to solve the above problems, various studies for preparing a sustained release or controlled release formulation of cilostazol have been conducted, and various studies for improving the solubility and absorption of cilostazol have been made.

As a technique for sufficiently releasing a drug from a sustained release formulation even after reaching the lower digestive tract, a matrix formulation prepared by using a methacrylic acid-based enteric polymer is known (Japanese Patent Publication No. 4 (1992) -43049). Japanese Patent Application Laid-Open No. 6 (1994) -199657, US Patent No. 4,968,508, US Patent Publication No. 2006/0159753), and these formulations have low solubility due to small surface area and poor solubility with slow dissolution rate. In the case of preparations containing drugs, it may cause an obstacle to drug release.

In addition, in WO00 / 057881 and US 2002/0058066, the outer layer of the tablet causes the sustained release of the drug in the upper gastrointestinal tract (small intestine), whereas in the lower intestine and the large intestine the core tablet of the tablet disintegrates. A preparation for the release of antiseptic drugs is disclosed, and WO2005 / 023225 discloses dissolving cilostazol in an organic solvent and then including an additive such as microcrystalline cellulose, lactose, mannitol, croscarmellose sodium, and the like. Sustained-release formulations of cilostazol obtained by adsorbing on a porous inert carrier to increase drug solubility and then mixed with sustained-release polymers have been proposed.However, the manufacturing process is complicated or the size of the whole tablet is increased due to the large amount of additives. There are disadvantages that can lead to discomfort.

On the other hand, Korean Patent No. 10-1008540 achieves a dissolution rate suitable for once-a-day administration by formulating a sustained release matrix using carbomer and hydroxypropylmethylcellulose, but there is a problem that the dissolution rate between the individual tablets is large. .

In order to solve the sustained release formulation of cilostazol, which is very poorly soluble in water, the present inventors have shown a dissolution rate suitable for once-a-day administration when a neutral water-insoluble methacrylic acid copolymer is used as a sustained release matrix base. The present invention has been completed and found to have an advantageous effect as a sustained release formulation as well as a slow release, and to be able to uniformly mix with an excipient during formulation using a wet granulation method, thereby increasing the fluidity and being suitable for mass production.

Accordingly, an object of the present invention is to provide a cilostazol sustained-release preparation comprising cilostazol or a pharmaceutically acceptable salt thereof and a neutral water-insoluble methacrylic acid copolymer as a sustained-release matrix base.

The present invention also provides a cilostazol sustained-release preparation comprising a mixture of a neutral water-insoluble methacrylic acid copolymer and hydroxypropylmethylcellulose as cilostazol or a pharmaceutically acceptable salt thereof and a sustained-release matrix base. For the purpose of

In accordance with this object, the present invention provides a cilostazol sustained release formulation comprising a cilostazol or a pharmaceutically acceptable salt thereof and a neutral water insoluble methacrylic acid copolymer as a sustained release matrix base.

The neutral water insoluble methacrylic acid copolymer is composed of poly (ethylacrylate-methylmethacrylate) copolymer, poly (ethylacrylate-methylmethacrylate-trimethylaminoethylmethacrylate chloride) copolymer and mixtures thereof It may be selected from the group.

The poly (ethyl acrylate-methyl methacrylate) copolymer may be a copolymer having a weight ratio of ethyl acrylate and methyl methacrylate of about 2: 1.

The poly (ethyl acrylate-methyl methacrylate-trimethylaminoethyl methacrylate chloride) copolymer has a weight ratio of ethyl acrylate, methyl methacrylate and trimethylaminoethyl methacrylate chloride of about 1: 2: 0.2 or about It may be a copolymer of 1: 2: 0.1.

The neutral water-insoluble methacrylic acid copolymer is Eudragit NE 30D, Eudragit NE 40D, Eudragit NE 40D, Eudragit NM 30D, Eudragit RL 100 (Eudragit RL 100), Eudragit RL PO (Eudragit RL PO), Eudragit RL 30D, Eudragit RL 12.5, Eudragit RL 12.5, Eudragit RS 100, Eudragit RL PO It may be one or more selected from the group consisting of Eudragit RS PO, Eudragit RS 30D, Eudragit RS 12.5, and the like.

The sustained-release preparation may include about 10 to 40 parts by weight of the neutral water insoluble methacrylic acid copolymer based on 100 parts by weight of cilostazol, and may preferably include about 13 to 33 parts by weight. If the content of the neutral water insoluble methacrylic acid copolymer is less than about 10 parts by weight, the matrix of the tablet is partially damaged and the tablet disintegrates. When the content of the neutral water insoluble methacrylic acid copolymer exceeds about 40 parts by weight, the hardness of the tablet becomes excessively low.

According to another object of the present invention, the present invention relates to a neutral water-insoluble methacrylic acid copolymer and hydroxypropylmethylcellulose (hypromellose, HPMC) as cilostazol or a pharmaceutically acceptable salt thereof and a sustained-release matrix base. It provides a cilostazol sustained release formulation comprising a mixture of.

The neutral water insoluble methacrylic acid copolymer is composed of poly (ethylacrylate-methylmethacrylate) copolymer, poly (ethylacrylate-methylmethacrylate-trimethylaminoethylmethacrylate chloride) copolymer and mixtures thereof It may be selected from the group.

The poly (ethyl acrylate-methyl methacrylate) copolymer may be a copolymer having a weight ratio of ethyl acrylate and methyl methacrylate of about 2: 1.

The poly (ethyl acrylate-methyl methacrylate-trimethylaminoethyl methacrylate chloride) copolymer has a weight ratio of ethyl acrylate, methyl methacrylate and trimethylaminoethyl methacrylate chloride of about 1: 2: 0.2 or about It may be a copolymer of 1: 2: 0.1.

The neutral water-insoluble methacrylic acid copolymer is Eudragit NE 30D, Eudragit NE 40D, Eudragit NE 40D, Eudragit NM 30D, Eudragit RL 100 (Eudragit RL 100), Eudragit RL PO (Eudragit RL PO), Eudragit RL 30D, Eudragit RL 12.5, Eudragit RL 12.5, Eudragit RS 100, Eudragit RL PO It may be one or more selected from the group consisting of Eudragit RS PO, Eudragit RS 30D, Eudragit RS 12.5, and the like.

The sustained-release preparation may include about 15 to 40 parts by weight of a neutral water-insoluble methacrylic acid copolymer and hydroxypropylmethylcellulose based on 100 parts by weight of cilostazol, and preferably about 19 to 33 parts by weight. It may include. When the content of the mixture is less than about 15 parts by weight, the release time of cilostazol is shortened, and the amount of elution per unit time increases, which may cause side effects. On the other hand, if the content of the mixture exceeds about 40 parts by weight, the cilostazol release time is long, and thus the amount of drug eluted per unit time decreases, so that sufficient efficacy is not expected.

The sustained release preparation may include a mixture of a neutral water insoluble methacrylic acid copolymer and hydroxypropylmethylcellulose in a weight ratio of about 1: 0.6 to 1: 4.2.

The hydroxypropyl methyl cellulose may have a viscosity of about 80,000 to 120,000 cps. If the viscosity is less than about 80,000 cps, the required amount of hydroxypropylmethylcellulose is increased so that the size of the tablet becomes excessively large, and if the viscosity is greater than about 120,000 cps, it is not uniformly mixed with cilostazol and other excipients. .

Sustained release formulations according to the invention include tablets; Granules; Pellets; Mini tablets; And it may be selected from the group consisting of granules, pellets or mini-filled capsules.

The sustained-release preparation of the present invention uses a methacrylic acid copolymer which is neutral water insoluble as a sustained release matrix base, which enables uniform mixing with excipients when formulated using a wet granulation method, thereby increasing fluidity and being suitable for mass production. It is effective, and shows a dissolution rate suitable for once-a-day administration, but it is very advantageous as a sustained release formulation due to a small variation in dissolution rate.

1 is a graph showing the dissolution test results of the sustained release formulations of Examples 1 to 3 of the present invention using a neutral water-insoluble methacrylic acid copolymer (eudragit) as a sustained-release base.
Figure 2 is a graph showing the dissolution test results of the sustained release formulations of Examples 4 and 5 of the present invention using a neutral water-insoluble methacrylic acid copolymer (eudragit) and hydroxypropylmethylcellulose as a sustained-release base.
Figure 3 is a graph showing the dissolution test results of cilostazol sustained-release tablet (comparative example) using a carbomer and hydroxypropylmethyl cellulose as a sustained-release base.

In one aspect of the invention, a cilostazol sustained release formulation is provided comprising cilostazol or a pharmaceutically acceptable salt thereof and a neutral water insoluble methacrylic acid copolymer as a sustained release matrix base.

Methacrylic acid copolymers are available in a variety of products under the trade name Eudragit from Evonik Industries, Germany. Since Eudragit was first introduced as a drug-coating base in 1953 because of its weakly alkaline and gastrointestinal resistance, Eudragit has been released with anionic, cationic and neutral properties. These polymers exhibit a variety of solubility profiles depending on pH / independence, and have been applied as a matrix of tablets in general in situ or granulation processes, as well as coating bases with various properties.

Cilostazol is a BCS II group drug with low solubility and high permeability. In addition, the absorption rate of the cilostazol drug itself is known to be higher in the upper small intestine than in the lower small intestine. Therefore, it is important to keep the matrix form of cilostazol for a long time to deliver the drug to the lower part of the small intestine. The present inventors have found that the neutral water-insoluble methacrylic acid copolymer having low permeability to water is particularly suitable as a sustained-release matrix base for sustained release of cilostazol, showing a dissolution rate suitable for once-a-day administration, but with a small variation in dissolution rate. It has been found to be advantageous for the sustained release of cilostazol, and to allow for uniform mixing with excipients when formulated using wet granulation, thereby increasing fluidity and being suitable for mass production. The present invention is based on this.

Neutral water-insoluble methacrylic acid copolymers that can be used as the sustained release matrix base in the present invention are poly (ethylacrylate-methylmethacrylate) copolymers, poly (ethylacrylate-methylmethacrylate-trimethylaminoethylmethacrylate Late chloride) copolymer and mixtures thereof.

In the present invention, the poly (ethyl acrylate-methyl methacrylate) copolymer which can be used as the sustained release matrix base may be a copolymer having a weight ratio of ethyl acrylate and methyl methacrylate of about 2: 1.

Poly (ethylacrylate-methylmethacrylate-trimethylaminoethylmethacrylate chloride) copolymers that can be used as the sustained release matrix base in the present invention include ethylacrylate, methylmethacrylate and trimethylaminoethylmethacrylate chloride. It may be a copolymer having a weight ratio of about 1: 2: 0.2 or about 1: 2: 0.1.

The neutral water-insoluble methacrylic acid copolymer is Eudragit NE 30D, Eudragit NE 40D, Eudragit NE 40D, Eudragit NM 30D, Eudragit RL 100 (Eudragit RL 100), Eudragit RL PO (Eudragit RL PO), Eudragit RL 30D, Eudragit RL 12.5, Eudragit RL 12.5, Eudragit RS 100, Eudragit RL PO It may be one or more selected from the group consisting of Eudragit RS PO, Eudragit RS 30D, and Eudragit RS 12.5. Particularly preferred are Eudragit RS 100, Eudragit RS PO, Eudragit RS 30D, or Eudragit RS 12.5. Can be.

The sustained-release preparation may include about 10 to 40 parts by weight of the neutral water insoluble methacrylic acid copolymer based on 100 parts by weight of cilostazol, and more preferably about 13 to 33 parts by weight. If the content of the neutral water insoluble methacrylic acid copolymer is less than about 10 parts by weight, the matrix of the tablet is partially damaged and the tablet disintegrates. When the content of the neutral water insoluble methacrylic acid copolymer exceeds about 40 parts by weight, the hardness of the tablet becomes excessively low.

As a result of the dissolution test of Examples 1 to 3 using only Eudragit, a neutral water-insoluble methacrylic acid copolymer, as a sustained release base, the variation in dissolution rate was compared with a comparative formulation using carbomer and hydroxypropylmethylcellulose as a sustained release base. It was found that it can be reduced, and showed a dissolution rate pattern equivalent to that of the comparative formulation (Experimental Example 1).

In another aspect of the invention, a cilostazol sustained release formulation comprising a mixture of a neutral water insoluble methacrylic acid copolymer and hydroxypropylmethylcellulose as cilostazol or a pharmaceutically acceptable salt thereof and a sustained release matrix base Is provided.

When the neutral water-insoluble methacrylic acid copolymer and hydroxypropyl methyl cellulose are used together, the matrix in the sustained-release tablet is strengthened, and the tablets are swelled and the tablets are released by maintaining the matrix of the tablets. ) To maintain a constant dissolution rate.

In the present invention, the neutral water-insoluble methacrylic acid copolymer is a poly (ethyl acrylate-methyl methacrylate) copolymer, a poly (ethyl acrylate-methyl methacrylate-trimethylaminoethyl methacrylate chloride) copolymer and its It may be selected from the group consisting of a mixture.

In the present invention, the poly (ethyl acrylate-methyl methacrylate) copolymer may be a copolymer having a weight ratio of ethyl acrylate and methyl methacrylate of about 2: 1.

In the present invention, the poly (ethyl acrylate-methyl methacrylate-trimethylaminoethyl methacrylate chloride) copolymer has a weight ratio of ethyl acrylate, methyl methacrylate and trimethylaminoethyl methacrylate chloride of about 1: 2: 0.2 or about 1: 2: 0.1.

The neutral water-insoluble methacrylic acid copolymer is Eudragit NE 30D, Eudragit NE 40D, Eudragit NE 40D, Eudragit NM 30D, Eudragit RL 100 (Eudragit RL 100), Eudragit RL PO (Eudragit RL PO), Eudragit RL 30D, Eudragit RL 12.5, Eudragit RL 12.5, Eudragit RS 100, Eudragit RL PO It may be one or more selected from the group consisting of Eudragit RS PO, Eudragit RS 30D, Eudragit RS 12.5, and the like. Particularly preferred are Eudragit RS 100, Eudragit RS PO, Eudragit RS 30D, or Eudragit RS 12.5. Can be.

The sustained-release preparation may include about 15 to 40 parts by weight of the neutral water insoluble methacrylic acid copolymer and hydroxypropylmethylcellulose based on 100 parts by weight of cilostazol, and more preferably about 19 to 33 parts by weight. It may include. When the content of the mixture of the neutral water insoluble methacrylic acid copolymer and hydroxypropyl methyl cellulose is less than about 15 parts by weight, the release time of the cilostazol is shortened, and the amount of elution per unit time is increased, which may cause side effects. On the other hand, if the content of the mixture exceeds about 40 parts by weight, the cilostazol release time is long, and thus the amount of drug eluted per unit time decreases, so that sufficient efficacy is not expected.

The sustained release preparation may include a mixture of a neutral water insoluble methacrylic acid copolymer and hydroxypropylmethylcellulose in a weight ratio of about 1: 0.6 to 1: 4.2. If the weight ratio is less than about 1: 0.6, it is difficult to form a matrix in tablets, and the delay of drug release is reduced.If the weight ratio is greater than about 1: 4.2, the dissolution rate of cilostazol is lowered and cilostazol and neutral water insoluble methacrylic acid Uniform mixing between the copolymers is difficult. Preferably about 1: 0.8 to 1: 3.5 mixing is possible.

The hydroxypropyl methyl cellulose may have a viscosity of 80,000 to 120,000 cps. Preferably, it may be 90,000 to 110,000 cps. If the viscosity is less than 80,000 cps, a large amount of hydroxypropylmethylcellulose is required, and the size of the tablet becomes large. If the viscosity exceeds 120,000 cps, uniform mixing with cilostazol becomes difficult. Even at the same viscosity, it is preferable to use a product having a more uniform physical form with good dispersion of particles.

Neutral water-insoluble methacrylic acid copolymer as a sustained release base was obtained by dissolution test of Examples 4 and 5 using Eudragit and hydroxypropylmethylcellulose, and compared with carbomer and hydroxypropylmethylcellulose as a sustained release base. It was found that the variation in dissolution rate could be reduced compared to the formulation, and the dissolution rate pattern was the same as that of the comparative formulation (Experimental Example 1).

Sustained release formulations according to the invention include tablets; Granules; Pellets; Mini tablets; And it may be selected from the group consisting of granules, pellets or mini-filled capsules.

Sustained release formulations according to the invention may further comprise a pharmaceutically acceptable excipient. The pharmaceutically acceptable excipients may include diluents, binders, lubricants, disintegrants, solubilizers and the like.

The diluent serves to increase the volume of the formulation, at least one from the group consisting of lactose, dextrin, mannitol, sorbitol, starch, microcrystalline cellulose, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, calcium carbonate, sugars and mixtures thereof The selected one may be used, but is not limited thereto.

The binder can be used by dissolving in a solvent, and serves to increase the binding power of the formulation. Polyvinylpyrrolidone (povidone), copovidone, gelatin, starch, sucrose, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, One or more selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl alkyl cellulose and mixtures thereof may be used, but is not limited thereto. Specifically, povidone may be used as the binder, povidone K-15, K-30, or K-90 is preferred, and povidone K-30 is more preferred.

The glidant improves the fluidity of the granules to increase the filling to the die, which is the lower part of the tableting machine, and reduces the friction between the granules and the punch-die which is the top of the granules and the tableting machine. Lubricating agent, such as stearic acid, magnesium stearate, calcium stearate, sodium lauryl sulfate, glyceryl monostearate, sodium stearyl fumarate, talc, Corn starch, carnauba wax, colloidal silicon oxide, magnesium silicate, synthetic aluminum silicate, hardened oil, white lead, titanium oxide, microcrystalline cellulose, macrogol 4000 and 6000, isopropyl myristate, calcium hydrogen phosphate, and mixtures thereof One or more selected from the group consisting of may be used, but is not limited thereto.

The disintegrant is used to absorb the moisture to promote disintegration of the drug to improve the dissolution of the drug as crosscamellose sodium, sodium starch glycolate, pregelatinized star Pregelatinized starch, microcrystalline cellulose, crospovidone (cross-linked povidone), other commercially available polyvinylpyrrolidone (PVP, Povidone), carboxymethylcellulose calcium, carboxymethylcellulose sodium At least one selected from low substituted hydroxypropylcellulose (low substituted), alginic acid, colloidal silicon oxide, powdered cellulose, starch, sodium alginate, and mixtures thereof Can be used, but is not limited thereto.

The solubilizer may be polyoxyethylene sorbitan fatty acid esters such as sodium lauryl sulfate, polysorbate, colloidal silicon dioxide, etc., to assist in dissolution of poorly soluble drugs, but is not limited thereto.

Preferably, the pharmaceutically acceptable excipient is lactose, sucrose, dextrin, mannitol, sorbitol, microcrystalline cellulose, povidone, copovidone, methylcellulose, ethylcellulose, hydroxypropylalkylcellulose, croscarmellose sodium, carboxymethylcellulose Calcium, carboxymethylcellulose sodium, sodium lauryl sulfate, crospovidone, starch, dextrin, pregelatinized starch, colloidal silicon oxide, stearic acid, magnesium stearate, calcium stearate, glyceryl monostearate, sodium It may be one or more selected from the group consisting of stearyl fumarate, talc and mixtures thereof, but is not limited thereto.

Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are intended to illustrate the present invention more specifically, but the scope of the present invention is not limited by these examples.

Example  1 to 3: neutral Water insoluble  Methacrylic acid copolymer Sustained release  Preparation of Sustained-Release Formulations Used as Matrix Base

To the sustained-release tablet was prepared using the following preparation method according to each component and content shown in Table 1. Povidone K-30 was first dissolved in 100% ethanol and Eudragit RS PO was dispersed in 90% ethanol aqueous solution to make a 20 w / w% solution. Next, use a speed mixer to mix cilostazol, microcrystalline cellulose, sodium lauryl sulfate, and colloidal silicon oxide well, and then use a povidone K-30 binder solution and a 20% Eudragit solution to prepare a cylindrical granulator. Wet granules at. The granules thus prepared were dried in a drying oven (40 ° C.) for at least 12 hours, sieved to 20mesh, and further mixed with Eudragit RS PO (except Example 1) and magnesium stearate in the semi-finished product. It was tableted according to the weight per tablet described in.

division
Ingredient Name
Example 1 Example 2 Example 3 Content (mg) Content (mg) Content (mg) chief ingredient Cilostazol 200.0 200.0 200.0 Excipient Microcrystalline cellulose 100.0 100.0 100.0 Excipient Sodium lauryl sulfate 20.0 20.0 20.0 Excipient Colloidal silicon dioxide 10.0 10.0 10.0 Sustained release Eudragit RS PO 26.4 38.8 64.8 Binder Povidone K-30 6.0 6.0 6.0 Lubricant Magnesium stearate 8.0 8.0 8.0 1 tablet gross weight 370.4 382.8 408.8

Example  4 to 5: neutral Water insoluble  Methacrylic acid copolymer Hydroxypropylmethylcellulose Sustained release  Preparation of Sustained-Release Formulations Used as Matrix Base

Sustained-release tablets were prepared by using the following preparation methods according to the ingredients and the contents shown in Table 2 below. Povidone K-30 was first dissolved in 100% ethanol and Eudragit RS PO was dispersed in 90% ethanol aqueous solution. Next, using a speed mixer, cilostazol, microcrystalline cellulose, sodium lauryl sulfate, colloidal silicon oxide, and 100,000 cps hypromellose were mixed well, and then the povidone K-30 binder solution and the eudragit solution were prepared. Wet granules were used in the cylindrical granulator. The granules thus prepared were dried in a drying oven (40 ° C.) for at least 12 hours and stipulated in a 20mesh sieve, and then further mixed with magnesium stearate in the sintered semi-finished product, which was tableted to the weight per tablet described below.

division
Ingredient Name
Example  4 Example 5 Content (mg) Content (mg) chief ingredient Cilostazol 200.00 200.00 Excipient Microcrystalline cellulose 100.00 100.00 Excipient Sodium lauryl sulfate 20.00 20.00 Excipient Colloidal Silicon Oxide 10.00 10.00 Sustained release Hypromellose (100,000 cps) 30.00 30.00 Sustained release Eudragit RS PO 8.70 34.80 Binder Povidone K-30 6.00 6.00 Lubricant Magnesium stearate 8.00 8.00 1 tablet gross weight 382.70 408.80

Comparative example  1 to 3: Sustained release  As a base Carbomer  And Hydroxypropylmethylcellulose Preparation of Sustained-Release Formulation Using Gas Mixtures

According to the components and contents shown in Table 3 below, the sustained-release tablet was prepared using the following preparation method. Povidone K-30 was first dissolved in ethanol. Next, using a speed mixer, cilostazol, microcrystalline cellulose, sodium lauryl sulfate, colloidal silicon oxide, 100,000 cps hypromellose, and carbomer were mixed well, using the povidone K-30 binder solution prepared above. Wet granulation was carried out in a cylindrical granulator. The granules thus prepared were dried in a drying oven (40 ° C.) for at least 12 hours and stipulated in a 20mesh sieve, and then further mixed with magnesium stearate in the sintered semi-finished product, which was tableted to the weight per tablet described below.

division
Ingredient Name
Comparative Example 1 Comparative Example 2 Comparative Example 3 Content (mg) Content (mg) Content (mg) chief ingredient Cilostazol 200.0 200.00 200.0 Excipient Microcrystalline cellulose 120 110 100 Excipient Sodium lauryl sulfate 15.0 22.0 24.0 Excipient Colloidal Silicon Oxide 15.0 8.0 6.0 Sustained release Hypromellose (100,000 cps) 28.0 32.0 34.0 Sustained release Carbomer 12.0 8.0 6.0 Binder Povidone K-30 6.0 8.0 10.0 Lubricant Magnesium stearate 10.0 10.0 10.0 1 tablet gross weight 406.0 398.0 390.0

Experimental Example 1: Dissolution test of cilostazol sustained release formulation

A certain amount of cilostazol sustained-release tablet prepared in Examples and Comparative Examples was eluted by the Korean Pharmacopoeia dissolution test method. As an eluate, 0.4 W / W% sodium lauryl sulfate aqueous solution was used. The elution method was paddle method, the eluent 900 ml, the stirring speed was 75 rpm, and the elution temperature was performed at 37 ± 0.5 ° C. 5 ml of the sample was taken at 1.5, 2, 4, 5, 6, 10 and 24 hours, and the same amount of eluent was added. Analytical conditions were quantified cilostazol by using a UV / Vis spectrophotometer of the solution obtained in the above dissolution test filtered with a 0.45㎛ membrane filter. The analysis wavelength was 257 nm.

time
(hr)
Dissolution rate (%) Example 1 Example 2 Example 3 Example 4 Example 5 Comparative Example 1 Comparative Example 2 Comparative Example 3 1.5 6.3 (0.8) 12 (1.2) 16.2 (1.3) 16.2 (0.4) 12.7 (0.8) 16.3 (1.8) 14.0 (2.2) 14.1 (2.3) 2 18.8 (0.3) 24.4 (0.7) 26.4 (2.0) 30.0 (2.1) 25.7 (0.5) 27.5 (3.0) 26.4 (2.7) 24.4 (2.0) 4 25.5 (2.1) 34.6 (1.5) 36.2 (0.7) 42.4 (0.5) 39.2 (0.7) 42.5 (3.1) 36.6 (3.5) 36.2 (2.7) 5 28 (1.3) 36.4 (0.6) 40.4 (0.5) 57.7 (1.4) 53.3 (3.5) 57.7 (5.0) 52.0 (4.8) 50.8 (4.5) 6 34 (1.1) 45.2 (1.0) 49.3 (0.9) 75.8 (0.6) 69.4 (1.1) 72.4 (4.1) 65.2 (3.0) 63.3 (2.1) 10 54.2 (2.4) 66.4 (1.3) 74.6 (1.4) 95.3 (2.7) 99.1 (0.5) 95.9 (1.4) 85.3 (4.3) 84.3 (3.4) 24 74.3 (2.5) 84.9 (0.9) 87.7 (1.5) 99.5 (0.9) 99.5 (0.4) 99.5 (0.5) 98.4 (0.9) 97.4 (1.5)

* The parentheses indicate the standard deviation of individual dissolution rates.

As a result of the dissolution test of Examples 1 to 3 using only Eudragit as a sustained release base, the dissolution rate of Examples 1 to 3 was lower than that of Comparative Examples 1 to 3, but the dissolution rate pattern was comparable to that of Comparative Examples 1 to 3. It could be seen that.

In addition, in the dissolution test results of Examples 4 and 5 using HPMC and Eudragit as a sustained release base, Examples 4 and 5 also showed less variation in dissolution rate than Comparative Examples 1 to 3, but Comparative Examples 1 to 3 and It was found that the dissolution rate patterns were comparable.

Experimental Example  2: Evaluation of Physical Properties of Sustained Release Formulations

The hardness and thickness of the tablets were measured for evaluation of the physical properties of Examples 1 to 5 and Comparative Examples 1 to 3. In the hardness test, 10 tablets were taken for each tablet, and hardness was measured using a PTB-411 hardness tester manufactured by ERWEKA Hardness Pharma Test. The hardness measurement results are shown in Table 5.

Example 1 Example 2 Example 3 Example 4 Example 5 Comparative Example 1 Comparative Example 2 Comparative example  3 Hardness (Kpa) 9.5 9.3 7.8 9.5 9.4 9.5 9.4 9.3 Thickness (mm) 4.43 4.67 4.9 4.85 4.95 4.67 4.68 4.70

As a result of the measurement, it was confirmed that the hardness and thickness of each sustained release formulation were substantially different and suitable as the sustained release formulation.

Claims (15)

A cilostazol sustained release formulation comprising cilostazol or a pharmaceutically acceptable salt thereof and a neutral water insoluble methacrylic acid copolymer as a sustained release matrix base.
The method of claim 1, wherein the neutral water-insoluble methacrylic acid copolymer is poly (ethyl acrylate-methyl methacrylate) copolymer, poly (ethyl acrylate-methyl methacrylate-trimethyl amino ethyl methacrylate chloride) Cilostazol sustained release formulations selected from the group consisting of coalescing and mixtures thereof.
The cilostazol sustained-release preparation of claim 2, wherein the poly (ethylacrylate-methylmethacrylate) copolymer is a copolymer in which the weight ratio of ethylacrylate and methyl methacrylate is 2: 1.
3. The poly (ethylacrylate-methylmethacrylate-trimethylaminoethylmethacrylate chloride) copolymer according to claim 2, wherein the weight ratio of ethylacrylate, methylmethacrylate and trimethylaminoethylmethacrylate chloride is 1: Cilostazol sustained release preparations, which are copolymers of 2: 0.2 or 1: 2: 0.1.
The method according to claim 1, wherein the neutral water insoluble methacrylic acid copolymer is Eudragit NE 30D, Eudragit NE 40D, Eudragit NM 30D, Eudragit NM 30D Dragrat RL 100 (Eudragit RL 100), Eudragit RL PO (Eudragit RL PO), Eudragit RL 30D, Eudragit RL 30D, Eudragit RL 12.5, Eudragit RL 12.5, Eudragit RS 100 Cilostazol, which is at least one selected from the group consisting of RS 100), Eudragit RS PO, Eudragit RS 30D, and Eudragit RS 12.5. Sustained release preparations.
The cilostazol sustained-release preparation of claim 1, wherein the neutral water-insoluble methacrylic acid copolymer comprises 10 to 40 parts by weight based on 100 parts by weight of cilostazol.
A cilostazol sustained release formulation comprising a mixture of a neutral water-insoluble methacrylic acid copolymer and hydroxypropylmethylcellulose as cilostazol or a pharmaceutically acceptable salt thereof and a sustained release matrix base.
8. The method of claim 7, wherein the neutral water-insoluble methacrylic acid copolymer is poly (ethylacrylate-methylmethacrylate) copolymer, poly (ethylacrylate-methylmethacrylate-trimethylaminoethylmethacrylate chloride) Cilostazol sustained release formulations selected from the group consisting of coalescing and mixtures thereof.
The cilostazol sustained-release preparation of claim 8, wherein the poly (ethylacrylate-methylmethacrylate) copolymer is a copolymer in which the weight ratio of ethylacrylate and methyl methacrylate is 2: 1.
The method of claim 8, wherein the poly (ethyl acrylate-methyl methacrylate-trimethylaminoethyl methacrylate chloride) copolymer has a weight ratio of ethyl acrylate, methyl methacrylate and trimethylaminoethyl methacrylate chloride is 1: Cilostazol sustained release formulations which are copolymers of 2: 0.2 or 1: 2: 0.1.
The method of claim 7, wherein the neutral water-insoluble methacrylic acid copolymer is Eudragit NE 30D, Eudragit NE 40D, Eudragit NM 30D, Eudragit NM 30D Dragrat RL 100 (Eudragit RL 100), Eudragit RL PO (Eudragit RL PO), Eudragit RL 30D, Eudragit RL 30D, Eudragit RL 12.5, Eudragit RL 12.5, Eudragit RS 100 Cilostazol, which is at least one selected from the group consisting of RS 100), Eudragit RS PO, Eudragit RS 30D, and Eudragit RS 12.5. Sustained release preparations.
8. The cilostazol sustained-release preparation of claim 7, wherein the cilostazol sustained-release preparation contains 15 to 40 parts by weight of a mixture of the neutral water-insoluble methacrylic acid copolymer and hydroxypropylmethylcellulose.
8. The cilostazol sustained-release preparation of claim 7, wherein the neutral water-insoluble methacrylic acid copolymer and a mixture of hydroxypropylmethylcellulose are included in a weight ratio of 1: 0.6 to 1: 4.2.
8. The cilostazol sustained-release preparation of claim 7, wherein the hydroxypropylmethylcellulose has a viscosity of 80,000 to 120,000 cps.
The method of claim 1, further comprising: tablets; Granules; Pellets; Mini tablets; And sustained release preparations selected from the group consisting of granules, pellets or mini-filled capsules.

Images